News - Roche, Anti-Arthritics/Rheumatics


Popular Filters

1 to 25 of 30 results

Product launches to fuel lupus market growth


The systemic lupus erythematosus (SLE) treatment market in the seven major countries (7MM) will increase…

Anti-Arthritics/RheumaticsBenlystaBristol-Myers SquibbEli LillyepratuzumabGlaxoSmithKlineGlobalImmuPharmaLupuzorMerck SeronoOrenciaPharmaceuticalRituxanRochetabalumabUCB

Pipeline innovation bodes well for systemic lupus erythematosus market


While the systemic lupus erythematosus (SLE) treatment market is predominantly limited to GlaxoSmithKline’s…

AmgenAnti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineImmuPharmaLupuzorLymphoCideMarkets & MarketingPharmaceuticalRituxanRoche

Roche and Chugai’s SC RoActemra improves RA long term

Roche and Chugai’s SC RoActemra improves RA long term


Roche and its majority-owned Japanese subsidiary Chugai Pharmaceutical have announced that their RoActemra…

Anti-Arthritics/RheumaticsAsia-PacificChugai PharmaceuticalPharmaceuticalResearchRoActemraRoche

European prescribing attitudes for rheumatoid arthritis post-ADACTA

European prescribing attitudes for rheumatoid arthritis post-ADACTA


Results from the ADACTA trial, which showed that Swiss drug major Roche’s RoActemra (tocilizumab) is…

AbbVieAnti-Arthritics/RheumaticsBiotechnologyEuropeHumiraMarkets & MarketingPfizerRoActemraRochetofactinib

Genentech’s SC Actemra approved by US FDA for severe RA

Genentech’s SC Actemra approved by US FDA for severe RA


Genentech has announced that the US Food and Drug Administration has approved a subcutaneous formulation…

ActemraAnti-Arthritics/RheumaticsGenentechNorth AmericaPharmaceuticalRegulationRoche

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan


The US Food and Drug Administration has approved changes to the prescribing information of the immune-suppressing…

Anti-Arthritics/RheumaticsArzerraBiogen IdecGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRituxanRoche

EU5 rheumatologits rate Rituxan and Benlysta for Lupus


Rheumatologists in the top European nations ( EU5) countries (France, Germany, Italy, Spain, UK) give…

Anti-Arthritics/RheumaticsBenlystaBiogen IdecBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingOrenciaPharmaceuticalRituxanRoche

Russia's R-Pharm to develop UCB's olokizumab for rheumatoid arthritis


Belgium's leading pharma company UCB (Euronext Brussels: UCB) said today (July 4) that it has granted…


Chugai gains Japanese approval for Perjeta and Bonviva


Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) said this morning (June 28) that it has obtained…

Anti-Arthritics/RheumaticsAsia-PacificBonvivaChugai PharmaceuticalOncologyPerjetaPharmaceuticalRegulationRoche

Therapy's induction of remission an attribute that most influences Rxing decisions in rheumatoid arthritis


The majority of US and European rheumatologists surveyed by health care advisory firm Decision Resources…

AbbVieActemraAnti-Arthritics/RheumaticsEisaiEuropeHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalRocheTakeda PharmaceuticalsXeljanz

Regulatory briefs: Sanofi's Fluzone; Roche' RoActemra; Takeda's Rienso


French pharma major Sanofi (Euronext: SAN) today (June 10) announced that the US Food and Drug Administration…

Anti-Arthritics/RheumaticsBiotechnologyPharmaceuticalRegulationRocheSanofiTakeda PharmaceuticalsVaccines

Proposal to list Roche's Neulastim and Actemra in New Zealand


New Zealand's Pharmaceutical Management Agency PHARMAC has announce the approval of a proposal to list…


New Zealand considers listing of Neulastim and Actemra


New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list pegfilgrastim…


Roche's RoActemra shows superiority to Humira in rheumatoid arthritis


Over 50% of rheumatoid arthritis patients can achieve low disease activity or remission with Swiss drug…


FDA Approves Abraxane for NSCLC and expands indication for Actemra


The US Food and Drug Administration on Friday approved biotech firm Celgene's (Nasdaq: CELG) Abraxane…

AbraxaneActemraAnti-Arthritics/RheumaticsBiotechnologyCelgeneGenentechNorth AmericaOncologyPharmaceuticalRegulationRoche

Roche's RoActemra beats leading rival Humira in RA study; other news from EULAR


Swiss drug major Roche (ROG: SIX) yesterday released new data from the ADACTA study which showed that…

Abbott LaboratoriesAnti-Arthritics/RheumaticsHumiraPharmaceuticalResearchRoActemraRoche

EMA confirms Roche's MabThera made at Vacaville site poses no health risk


Following a quality review of the genetically engineered monoclonal antibody MabThera, the European Medicines…


Mylan settles over Brovana; launches generic Boniva in UK and Italy


US generic drugs major Mylan (Nasdaq: MYL) has entered into an agreement with Sunovion Pharmaceuticals,…

Anti-Arthritics/RheumaticsBonivaBrovanaDainippon Sumitomo PharmaEuropeGenericsMarkets & MarketingMylan LaboratoriesNorth AmericaPatentsRespiratory and PulmonaryRocheSunovion

UK NICE gives draft "No" to Benlysta, and negative final guidance for Tyverb and Herceptin


There was a batch of bad news emanating from the US drugs watchdog the National Institute for Health…

Anti-Arthritics/RheumaticsBenlystaEuropeGlaxoSmithKlineHerceptinOncologyPharmaceuticalPricingRare diseasesRegulationRocheTyverb

FDA approves first generics of Roche osteo drug Boniva


The US Food and Drug Administration yesterday approved the first generic versions of Boniva (ibandronate)…

Anti-Arthritics/RheumaticsApotexBonivaGenericsMylan LaboratoriesNorth AmericaOrchid HealthcareRegulationRoche

NICE backs Roche RoActemra, but with PAS discount


UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today recommended…


Mixed NICE views on Faslodex and RoActemra


There was mixed news this morning from the UK’s National Institute for Health and Clinical Excellence…


1 to 25 of 30 results

Back to top